Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Input metadata references "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report).
Reporting Date: November 10, 2016.
Period Covered: The filing announces the results of operations for the quarter ended September 30, 2016.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not contain specific numerical values for the following metrics:
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific comparative data or describe material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2016, were reported.
Guidance, Outlook, and Risks
Management Commentary: The filing states that results were reported via a press release attached as Exhibit 99.1. No specific commentary, guidance, or outlook is included in the text of the 8-K form itself.
Risks and Contingencies: The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 will not be treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Press Release (Exhibit 99.1), as they are not listed in the 8-K text.
- Confirm the correct registrant name is RXi Pharmaceuticals Corporation, distinct from the "Phio Pharmaceuticals" name in the request metadata.
- Review the full press release for any forward-looking statements or guidance that may have been issued alongside the results.
- Check subsequent filings to see if the information in this 8-K was later incorporated by reference into other SEC documents.